Clinical Trials Logo

Filter by:
  • Recruiting  
  • Page [1] ·  Next »
NCT ID: NCT06322498 Recruiting - Clinical trials for Cesarean Section Complications

Inflammation Markers in Fluid Aspirate From a Scarred Uterine vs. a Normal Uterine Cavity

Start date: January 18, 2023
Phase: N/A
Study type: Interventional

A prospective study that will take place in the hydrosonography clinic, comparing patients with an intact uterus to those who had a caesarean section. Eligible patients will preform a transvaginal ultrasound for evaluation of presence of a niche. After fixation of the transcervical catheter, we will flush 2 ml sterile NaCl 0.9% into the uterine cavity and aspirate the fluid. After collecting all samples, the samples will be snap frozen and stored at -80o C, until they undergo an immunological analysis.

NCT ID: NCT06321120 Recruiting - Clinical trials for Lenvatinib Treatment

Using Chronobiology to Improve Lenvatinib Efficacy

Start date: March 1, 2023
Phase: Early Phase 1
Study type: Interventional

The goal of this proof-of-concept clinical trial is to assess the efficacy and safety of chronobiology implementation into lenvatinib treatment regimens of thyroid cancer patients, via a mobile application. Participants will use a mobile application to follow variability-based physician approved drug administration schedules.

NCT ID: NCT06318325 Recruiting - Clinical trials for Development, Adolescent

Growth Process and Development of the Musculoskeletal System in Young Gymnasts

Start date: March 1, 2024
Phase:
Study type: Observational

assessment of the musculoskeletal system will be performed twice a year, for three years of young gymnasts.

NCT ID: NCT06314217 Recruiting - Clinical trials for Diabetic Macular Edema

Everads Injector in Suprachoroidal Administration of TA Suspension, for Treatment of Patients With DME

Start date: February 18, 2024
Phase: N/A
Study type: Interventional

This is an open-label pilot device study. The aim of the study is to evaluate the safety and performance of Everads Injector following single injection of suspension approved for ocular use into the suprachoroidal space. The study population is patients diagnosed with diabetic macular edema (DME) that were previously treated. 10 adult subjects are expected to be enrolled based on the inclusion-exclusion criteria. The study will involve 6 visits during a period of 6 weeks

NCT ID: NCT06305611 Recruiting - Kawasaki Disease Clinical Trials

European and North Indian Cohort of KaWasaki dIsease

Start date: July 13, 2021
Phase:
Study type: Observational

Kawasaki disease (KD) is currently the leading cause of acquired heart diseases in children in developed countries. Cardiac involvement is the main determinant of the long-term prognosis of these patients, as coronary aneurisms (CAAs) may lead to ischemic heart disease and even sudden death. The current standard of care for KD has consistently reduced CAAs frequency from 25-30% to about 5%. Unfortunately, 10-20% of KD patients results resistant to standard treatment leading to a major risk of cardiac complications. Thus, scoring systems have been constructed in order to identify patients likely to be resistant to IVIG and who may benefit from more aggressive initial therapy. Different scoring scales developed by Kobayashi, Egami et Sano had shown a good sensitivity (77-86%) and specificity (67-86%) in predicting IVIG unresponsiveness in Japanese populations. However, their predictive value was not confirmed by subsequent studies in different ethnic populations. Recently, the French Kawanet group have proposed a IVIG unresponsiveness score that provided good sensitivity and acceptable specificity in a non-Asian KD population even if it was not subsequent validated by an external study. In our study population, the achievement of specificity and sensitivity values for both scores consistent with those reported by the original studies (sensitivity 70% and specificity 80% for Kobayashi and sensitivity 77% and specificity 60% for Kawanet), will be considered a success.

NCT ID: NCT06298799 Recruiting - Obesity Clinical Trials

GENETIC VARIABILITY TO GLP1 TREATMENT

GLP1 treatment
Start date: October 1, 2023
Phase: N/A
Study type: Interventional

The goal of this retrospective study is to assess whether a selection of genetic variants may allow us to identify individuals who will have a satisfactory response after GLP-1 treatment in terms of weight loss, sugar level reduction, and adverse events. Participants will The study consists of a single visit at the diabetes unit clinic at the involved study sites. The following will be performed for every subject at the study screening enrollment visit: - Informed consent - Study eligibility (Inclusion / Exclusion criteria) - Collection of demographic data (age (date of birth), gender, ethnic origin) - General and T2DM medical history review (per subject file) - Concomitant medication review (at enrollment) - Physical attributes (Body Weight, Height, BMI) - Allocation to study cohort and study subgroup - Saliva and blood collection for genetic tests - Self-reported questionnaire for Ozempic (Semaglutide) experience

NCT ID: NCT06280222 Recruiting - Anxiety Clinical Trials

The Effectiveness of Virtual Reality on Anxiety Reduction in Women Undergoing Elective Egg Cryopreservation.

VRFORANXIETY
Start date: November 15, 2023
Phase: N/A
Study type: Interventional

A randomized trial assessing the effectiveness of virtual reality exposure prior to an oocyte retrieval procedure in terms of anxiety level .

NCT ID: NCT06258330 Recruiting - Solid Tumor Clinical Trials

Study of AM003 in Patients With Locally Advanced and Metastatic Solid Tumors

Start date: June 22, 2022
Phase: Phase 1
Study type: Interventional

This is a phase 1, first-in-human study to assess the safety and tolerability of AM003 in patients with locally advanced and metastatic solid tumors

NCT ID: NCT06258239 Recruiting - Post-operative Pain Clinical Trials

Influence of the Communication Between the Nursing Staff and the Patient on the Analgesic Treatment Effectiveness After Surgery

Start date: April 1, 2023
Phase: N/A
Study type: Interventional

Acute pain is a normal response to tissue injury or disease and has an important biological function. It is adaptive and promotes recuperation by restricting behaviors that might incur further tissue trauma. In the case of post-operative acute pain, the cause and time of the physical injury are known, and because the condition is self-limiting it requires only short-term care. However, if acute pain responses cannot be adequately suppressed, cardiac, pulmonary and neuroendocrine functions may be compromised, and the immune system suppressed. Inadequate management of post-operative acute pain is a major burden for healthcare services and can contribute to medical complications including inflammation of the respiratory tract, damage to the oxygen supply to the heart muscle, deep vein thrombosis, delayed healing as well as the development of chronic pain, more difficult to treat. In addition, suboptimal management of pain after surgery may impair sleep and have negative psychological effects, such as anxiety, fear and lack of sleep. Proper treatment of pain reduces morbidity, damages, treatment costs, improves the patient's quality of life and his chances of a full recovery. It is therefore essential that all patients undergoing surgery should receive adequate pain management. Despite years of advances in pain management, the mainstay of postoperative pain therapy in many settings is still opioids. Morphine is the most commonly used opioid to treat moderate to severe pain after surgery in the recovery unit. The growing concern about the significant side effects, addictions and costs of opioids as a drug treatment has led to an urgent need to identify other agents and approaches to postoperative pain management that are effective, safe and cheap. The main purpose of this study is to examine whether the type of communication between the nursing staff and the patient will affect the results of pain relief treatment in the postoperative recovery department. As a secondary objective, we will examine whether personality traits will predict the effectiveness of the treatment.

NCT ID: NCT06258109 Recruiting - Clinical trials for Pregnancy Complications

Risk of Recurrent CeAD After Pregnancy

LONG-RECAP
Start date: January 1, 2023
Phase:
Study type: Observational

Primary objective: To determine whether pregnancy increases the risk of recurrent CeAD and delayed stroke in women with prior CeAD based on long-term data. Methods: Multicentric, observational case-control study based on pooled individual patient data from several stroke centers. Primary endpoint: Primary composite outcome measure includes the following outcomes: (i) occurrence of recurrent CeAD, (ii) occurrence of ischemic or hemorrhagic stroke, (iii) death.